News

(RTTNews) - Bristol Myers Squibb (BMY) increased portions of its 2024 line-item guidance. The company now expects: non-GAAP EPS in a range of $0.60 - $0.90, revised from prior guidance range of $0.40 - $0.70; and total revenues at upper end of low single- digit range, revised from previous outlook of low single-digit increase. Analysts polled by Thomson Reuters expect the company to report profit per share of $0.51. Analysts' estimates typically exclude special items.

Second quarter GAAP net income attributable to company was $1.7 billion, or $0.83 per share, compared to $2.1 billion, or $0.99 per share, a year ago. Non-GAAP net earnings attributable to Bristol Myers Squibb was $4.2 billion, or $2.07 per share, compared to $3.7 billion, or $1.75 per share, prior year. Analysts on average had expected the company to earn $1.63 per share, according to figures compiled by Thomson Reuters.

Second quarter revenues were $12.2 billion, an increase of 9%, or 11% when adjusted for foreign exchange impacts, primarily driven by the Growth Portfolio and Eliquis. Analysts on average had estimated $11.55 billion in revenue. Growth Portfolio worldwide revenues increased to $5.6 billion compared to $4.7 billion, a growth of 18% on a reported basis, or 21% when adjusted for foreign exchange impacts.

Also, Bristol Myers Squibb announced that the Phase 3 trial evaluating the efficacy and safety of cendakimab in patients with eosinophilic esophagitis met both co-primary endpoints. The company will work with investigators to present results at an upcoming medical conference.

Shares of Bristol Myers Squibb are up 4% in pre-market trade on Friday.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.